Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Zacks.com on MSN2d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
2d
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Hosted on MSN2d
Why AbbVie Stock Was Getting Mashed on MondaySchizophrenia drug didn't do well in the lab Just before the market open on Monday, AbbVie revealed that its emraclidine ...
Like most major biotech players, Abbvie eyed M&A as a major strategy to build out its pipeline and chart a future. And ...
Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials of its experimental schizophrenia drug, emraclidine, showed no significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback